he key ingredient that made COVID so unique was a four amino acid sequence inserted into spike protein. So that's 12 nucleotides coding for four amino acids shut down planet earth for a couple of years. That's how powerful this is
for - example - leverage - progress trap - COVID - mix of 4 amino acids inserted into a spike protein
for - Youtube -Right way to eat sugar - No inflammation - health - diet - how to minimize insulin spike when eating sugar - Dr. Anshul Gupta M.D. 2024 Nov
summary - combine with protein or good faats to slow down sugar release - exercise 15 minutes after eating sugar - eat in the morning, not the evening - eat small portions - stevia and monkfruit are the only sugar substitutes
Iketani, S., Liu, L., Guo, Y., Liu, L., Huang, Y., Wang, M., Luo, Y., Yu, J., Yin, M. T., Sobieszczyk, M. E., Huang, Y., Wang, H. H., Sheng, Z., & Ho, D. D. (2022). Antibody Evasion Properties of SARS-CoV-2 Omicron Sublineages (p. 2022.02.07.479306). bioRxiv. https://doi.org/10.1101/2022.02.07.479306
Meng, B., Abdullahi, A., Ferreira, I. A. T. M., Goonawardane, N., Saito, A., Kimura, I., Yamasoba, D., Gerber, P. P., Fatihi, S., Rathore, S., Zepeda, S. K., Papa, G., Kemp, S. A., Ikeda, T., Toyoda, M., Tan, T. S., Kuramochi, J., Mitsunaga, S., Ueno, T., … Gupta, R. K. (2022). Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity. Nature, 1–1. https://doi.org/10.1038/s41586-022-04474-x
The post-1950 acceleration of the human imprint on the Earth System, particularly the 12 graphsthat show changes in Earth System structure and functioning, have played a central role in thediscussion around the formalisation of the Anthropocene as the next epoch in Earth history.Although there has been much debate around the proposed start date for the Anthropocene, thebeginning of the Great Acceleration has been a leading candidate (Zalasiewicz et al., 2012).
The Great Acceleration of socio-economic and earth system indicators after 1950 make it a good candidate as a Golden Spike for the start of the Anthropocene.
ReconfigBehSci on Twitter: “RT @COGUK_ME: The @CovidGenomicsUK Mutation Explorer https://t.co/x2zsrhKj8Y is now tracking the combinations of spike substitutions known…” / Twitter. (n.d.). Retrieved April 29, 2022, from https://twitter.com/SciBeh/status/1462782003787542529
Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W. (2021). The biological and clinical significance of emerging SARS-CoV-2 variants. Nature Reviews Genetics, 1–17. https://doi.org/10.1038/s41576-021-00408-x
nature. (2021, April 16). Coronavirus variants: Where do they come from? How do we spot them? What do they mean for COVID vaccines, and future of the pandemic? Https://t.co/NRbORu2hoF [Tweet]. @Nature. https://twitter.com/Nature/status/1383093697374474240
Haseltine, W. A. (n.d.). Birth Of The Omicron Family: BA.1, BA.2, BA.3. Each As Different As Alpha Is From Delta. Forbes. Retrieved 30 March 2022, from https://www.forbes.com/sites/williamhaseltine/2022/01/26/birth-of-the-omicron-family-ba1-ba2-ba3-each-as-different-as-alpha-is-from-delta/
Schencker, L. (n.d.). Chicago-area children’s hospitals see dramatic spikes in kids admitted with COVID-19, amid latest surge. Chicagotribune.Com. Retrieved March 25, 2022, from https://www.chicagotribune.com/coronavirus/ct-coronavirus-children-hospitalized-covid-advocate-20220106-xij5tr7jv5ghnhch2sz4ske7aa-story.html
Chatterjee, D., Tauzin, A., Marchitto, L., Gong, S. Y., Boutin, M., Bourassa, C., Beaudoin-Bussières, G., Bo, Y., Ding, S., Laumaea, A., Vézina, D., Perreault, J., Gokool, L., Morrisseau, C., Arlotto, P., Fournier, É., Guilbault, A., Delisle, B., Levade, I., … Finzi, A. (2022). SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-weeks interval between doses. Cell Reports, 0(0). https://doi.org/10.1016/j.celrep.2022.110429
Trevor Bedford. (2022, January 28). Omicron viruses can be divided into two major groups, referred to as PANGO lineages BA.1 and BA.2 or @nextstrain clades 21K and 21L. The vast majority of globally sequenced Omicron have been 21K (~630k) compared a small minority of 21L (~18k), but 21L is gaining ground. 1/15 [Tweet]. @trvrb. https://twitter.com/trvrb/status/1487105396879679488
Prof. Akiko Iwasaki. (2022, January 27). Vaccines that reduce infection & disease are needed to combat the pandemic. Here, @tianyangmao @BenIsraelow et al. Describe our new mucosal booster strategy, Prime and Spike, to induce such immunity via nasal delivery of unadjuvanted spike vaccine 🧵 (1/) https://biorxiv.org/content/10.1101/2022.01.24.477597v1 https://t.co/bcB5MFph9F [Tweet]. @VirusesImmunity. https://twitter.com/VirusesImmunity/status/1486510697332842498
Carreño, Juan Manuel, Hala Alshammary, Johnstone Tcheou, Gagandeep Singh, Ariel Raskin, Hisaaki Kawabata, Levy Sominsky, et al. ‘Activity of Convalescent and Vaccine Serum against SARS-CoV-2 Omicron’. Nature, 31 December 2021, 1–8. https://doi.org/10.1038/s41586-022-04399-5.
Pajon, R., Doria-Rose, N. A., Shen, X., Schmidt, S. D., O’Dell, S., McDanal, C., Feng, W., Tong, J., Eaton, A., Maglinao, M., Tang, H., Manning, K. E., Edara, V.-V., Lai, L., Ellis, M., Moore, K. M., Floyd, K., Foster, S. L., Posavad, C. M., … Montefiori, D. C. (2022). SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. New England Journal of Medicine, 0(0), null. https://doi.org/10.1056/NEJMc2119912
Marcus, A. A. (2022, January 13). COVID-19 spike protein paper earns an expression of concern. Retraction Watch. https://retractionwatch.com/2022/01/13/covid-19-spike-protein-paper-earns-an-expression-of-concern/
Eric Topol. (2021, November 27). View of key mutations of Omicron’s 50, with 30 in the spike protein, 15 in its receptor binding domain https://ft.com/content/42c5ff3d-e676-4076-9b9f-7243a00cba5e http://covariants.org @EllingUlrich @_b_meyer https://t.co/onMoNFVLFJ [Tweet]. @EricTopol. https://twitter.com/EricTopol/status/1464452102382448643
What do we know about the new B.1.1.529 coronavirus variant and should we be worried? (n.d.). Retrieved 10 December 2021, from https://www.gavi.org/vaccineswork/what-we-know-about-new-b11529-coronavirus-variant-so-far
New Covid variant: How worried should we be? (2021, November 25). BBC News. https://www.bbc.com/news/health-59418127
Devlin, H., & Kollewe, J. (2021, November 26). BioNTech says it could tweak Covid vaccine in 100 days if needed. The Guardian. https://www.theguardian.com/society/2021/nov/26/biontech-says-it-could-tweak-covid-vaccine-in-100-days-if-needed
Evaluating Omicron and Other COVID Variants to Ensure Test Effectiveness. (n.d.). Abbott. Retrieved December 3, 2021, from https://www.abbott.com/corpnewsroom/diagnostics-testing/monitoring-covid-variants-to-ensure-test-effectiveness.html
nference. (2021, November 27). Here is how B.1.1.529 (#Omicron #B11529) compares to Alpha, Beta, Gamma, Delta variants. Omicron has highest novel Spike mutations including striking cluster on the “crown” suggesting significant selection pressure & antigenic distinction from prior strains (Credits: Nference) https://t.co/4oZQbjhbG8 [Tweet]. @_nference. https://twitter.com/_nference/status/1464404770098229250
Meaghan Kall. (2021, November 26). B.1.1.529 in the UK • Designated a Variant Under Investigation (VUI) VUI-21NOV-01 • No cases in the UK 🇬🇧 to date • Enhanced case finding & rapid assessment is underway https://t.co/0DGvlgvdPR [Tweet]. @kallmemeg. https://twitter.com/kallmemeg/status/1464210457795907588
Interestingly, all four vaccine breakthrough infection subjects who had previous COVID-19 were seropositive for anti-membrane IgG during acute infection, while no breakthrough subjects without prior COVID-19 had detectable anti-membrane antibodies in the acute infection period (Figure 1I).
Vaccinated individuals that experience a breakthrough infection do not develop antibodies to the parts of the virus that is not encoded by the vaccine.
Sun, W., Liu, Y., Amanat, F., González-Domínguez, I., McCroskery, S., Slamanig, S., Coughlan, L., Rosado, V., Lemus, N., Jangra, S., Rathnasinghe, R., Schotsaert, M., Martinez, J. L., Sano, K., Mena, I., Innis, B. L., Wirachwong, P., Thai, D. H., Oliveira, R. D. N., … Palese, P. (2021). A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. Nature Communications, 12(1), 6197. https://doi.org/10.1038/s41467-021-26499-y
UK’s daily Covid deaths hit SEVEN-MONTH high of 223 while cases jump 13% in a week to 43,738 | Daily Mail Online. (n.d.). Retrieved October 25, 2021, from https://www.dailymail.co.uk/news/article-10108203/UKs-daily-Covid-deaths-hit-SEVEN-MONTH-high-223-cases-jump-13-week-43-738.html
Shrotri, M., Navaratnam, A. M. D., Nguyen, V., Byrne, T., Geismar, C., Fragaszy, E., Beale, S., Fong, W. L. E., Patel, P., Kovar, J., Hayward, A. C., & Aldridge, R. W. (2021). Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. The Lancet, 398(10298), 385–387. https://doi.org/10.1016/S0140-6736(21)01642-1
Farmer, B. (2021, May 5). While India suffers, other Asian countries are also seeing worrying Covid-19 spikes. The Telegraph. https://www.telegraph.co.uk/global-health/science-and-disease/india-suffers-asian-countries-also-seeing-worrying-covid-19/
McKinley, Jesse, and Luis Ferré-Sadurní. ‘Warnings Issued as Virus Cases Rise in New York’. The New York Times, 28 September 2020, sec. New York. https://www.nytimes.com/2020/09/28/nyregion/ny-coronavirus-cases.html.
Ferretti, A. P., Kula, T., Wang, Y., Nguyen, D. M., Weinheimer, A., Dunlap, G. S., Xu, Q., Nabilsi, N., Perullo, C. R., Cristofaro, A. W., Whitton, H. J., Virbasius, A., Olivier, K. J., Baiamonte, L. B., Alistar, A. T., Whitman, E. D., Bertino, S. A., Chattopadhyay, S., & MacBeath, G. (2020). COVID-19 Patients Form Memory CD8+ T Cells that Recognize a Small Set of Shared Immunodominant Epitopes in SARS-CoV-2. MedRxiv, 2020.07.24.20161653. https://doi.org/10.1101/2020.07.24.20161653
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., Dinnon, K. H., Elbashir, S. M., Shaw, C. A., Woods, A., Fritch, E. J., Martinez, D. R., Bock, K. W., Minai, M., Nagata, B. M., … Graham, B. S. (2020). SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature, 1–8. https://doi.org/10.1038/s41586-020-2622-0
Martino, C., Kellman, B. P., Sandoval, D. R., Clausen, T. M., Marotz, C. A., Song, S. J., Wandro, S., Zaramela, L. S., Benítez, R. A. S., Zhu, Q., Armingol, E., Vázquez-Baeza, Y., McDonald, D., Sorrentino, J. T., Taylor, B., Belda-Ferre, P., Liang, C., Zhang, Y., Schifanella, L., … Knight, R. (2020). Bacterial modification of the host glycosaminoglycan heparan sulfate modulates SARS-CoV-2 infectivity. BioRxiv, 2020.08.17.238444. https://doi.org/10.1101/2020.08.17.238444
Yonker, L. M., Neilan, A. M., Bartsch, Y., Patel, A. B., Regan, J., Arya, P., Gootkind, E., Park, G., Hardcastle, M., John, A. S., Appleman, L., Chiu, M. L., Fialkowski, A., Flor, D. D. la, Lima, R., Bordt, E. A., Yockey, L. J., D’Avino, P., Fischinger, S., … Fasano, A. (2020). Pediatric SARS-CoV-2: Clinical Presentation, Infectivity, and Immune Responses. The Journal of Pediatrics, 0(0). https://doi.org/10.1016/j.jpeds.2020.08.037
Glasgow, A., Glasgow, J., Limonta, D., Solomon, P., Lui, I., Zhang, Y., Nix, M. A., Rettko, N. J., Lim, S. A., Zha, S., Yamin, R., Kao, K., Rosenberg, O. S., Ravetch, J. V., Wiita, A. P., Leung, K. K., Zhou, X. X., Hobman, T. C., Kortemme, T., & Wells, J. A. (2020). Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. BioRxiv, 2020.07.31.231746. https://doi.org/10.1101/2020.07.31.231746
Sun, W., McCroskery, S., Liu, W.-C., Leist, S. R., Liu, Y., Albrecht, R. A., Slamanig, S., Oliva, J., Amanat, F., Schäfer, A., Dinnon, K. H., Innis, B. L., García-Sastre, A., Krammer, F., Baric, R. S., & Palese, P. (2020). A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine. BioRxiv, 2020.07.30.229120. https://doi.org/10.1101/2020.07.30.229120
Bangaru, S., Ozorowski, G., Turner, H. L., Antanasijevic, A., Huang, D., Wang, X., Torres, J. L., Diedrich, J. K., Tian, J.-H., Portnoff, A. D., Patel, N., Massare, M. J., Yates, J. R., Nemazee, D., Paulson, J. C., Glenn, G., Smith, G., & Ward, A. B. (2020). Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. BioRxiv, 2020.08.06.234674. https://doi.org/10.1101/2020.08.06.234674
Marshall, M. (n.d.). Everything you need to know about Russia’s coronavirus vaccine claims. New Scientist. Retrieved August 18, 2020, from https://www.newscientist.com/article/2251722-everything-you-need-to-know-about-russias-coronavirus-vaccine-claims/
Sky News. ‘Coronavirus: UK Records Highest Daily Number of COVID-19 Cases for Nearly Two Months’. Accessed 12 August 2020. https://news.sky.com/story/coronavirus-uk-records-highest-daily-number-of-covid-19-cases-for-nearly-two-months-12047385.
Correa, R., Du, W., & Liao, G. Y. (2020). U.S. Banks and Global Liquidity (Working Paper No. 27491; Working Paper Series). National Bureau of Economic Research. https://doi.org/10.3386/w27491
Ou, T., Mou, H., Zhang, L., Ojha, A., Choe, H., & Farzan, M. (2020). Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2. BioRxiv, 2020.07.22.216150. https://doi.org/10.1101/2020.07.22.216150
Hsieh, C.-L., Goldsmith, J. A., Schaub, J. M., DiVenere, A. M., Kuo, H.-C., Javanmardi, K., Le, K. C., Wrapp, D., Lee, A. G., Liu, Y., Chou, C.-W., Byrne, P. O., Hjorth, C. K., Johnson, N. V., Ludes-Meyers, J., Nguyen, A. W., Park, J., Wang, N., Amengor, D., … McLellan, J. S. (2020). Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science. https://doi.org/10.1126/science.abd0826
Havers, F. P., Reed, C., Lim, T., Montgomery, J. M., Klena, J. D., Hall, A. J., Fry, A. M., Cannon, D. L., Chiang, C.-F., Gibbons, A., Krapiunaya, I., Morales-Betoulle, M., Roguski, K., Rasheed, M. A. U., Freeman, B., Lester, S., Mills, L., Carroll, D. S., Owen, S. M., … Thornburg, N. J. (2020). Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2020.4130
Unemployment Paths in a Pandemic Economy. COVID-19 and the Labor Market. (n.d.). IZA – Institute of Labor Economics. Retrieved July 29, 2020, from https://covid-19.iza.org/publications/dp13294/
Clausen, T. M., Sandoval, D. R., Spliid, C. B., Pihl, J., Painter, C. D., Thacker, B. E., Glass, C. A., Narayanan, A., Majowicz, S. A., Zhang, Y., Torres, J. L., Golden, G. J., Porell, R., Garretson, A. F., Laubach, L., Feldman, J., Yin, X., Pu, Y., Hauser, B., … Esko, J. D. (2020). SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. BioRxiv, 2020.07.14.201616. https://doi.org/10.1101/2020.07.14.201616
Yurkovetskiy, L., Wang, X., Pascal, K. E., Tomkins-Tinch, C., Nyalile, T., Wang, Y., Baum, A., Diehl, W. E., Dauphin, A., Carbone, C., Veinotte, K., Egri, S. B., Schaffner, S. F., Lemieux, J. E., Munro, J., Rafique, A., Barve, A., Sabeti, P. C., Kyratsous, C. A., … Luban, J. (2020). Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant. BioRxiv, 2020.07.04.187757. https://doi.org/10.1101/2020.07.04.187757
How scientists know COVID-19 is way deadlier than the flu. (2020, July 2). Science. https://www.nationalgeographic.com/science/2020/07/coronavirus-deadlier-than-many-believed-infection-fatality-rate-cvd/
Robertson, C., & Mervosh, S. (2020, July 12). Pittsburgh Seemed Like a Virus Success Story. Now Cases Are Surging. The New York Times. https://www.nytimes.com/2020/07/12/us/coronavirus-pittsburgh-pennsylvania.html
Pell, Samantha, closeSamantha PellReporter covering the Washington CapitalsEmailEmailBioBioFollowFollowC, ace Buckner, closeC, and ace BucknerNational Basketball Association with an emphasis in covering the Washington Wizards EmailEmailBioBioFollowFollowJacqueline Dupree closeJacqueline DupreeNewsroom Intranet EditorEmailEmailBioBioFollowFollow. ‘Coronavirus Hospitalizations Rise Sharply in Several States Following Memorial Day’. Washington Post. Accessed 10 June 2020. https://www.washingtonpost.com/health/2020/06/09/coronavirus-hospitalizations-rising/.
Wang, C., Li, W., Drabek, D. et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun 11, 2251 (2020). https://doi.org/10.1038/s41467-020-16256-y
Spikes Spikes are a type of exploration Enabler Story in SAFe. Defined initially in Extreme Programming (XP), they represent activities such as research, design, investigation, exploration, and prototyping. Their purpose is to gain the knowledge necessary to reduce the risk of a technical approach, better understand a requirement, or increase the reliability of a story estimate. Like other stories, spikes are estimated and then demonstrated at the end of the Iteration. They also provide an agreed upon protocol and workflow that Agile Release Trains (ARTs) use to help determine the viability of Epics. Details Agile and Lean value facts over speculation. When faced with a question, risk, or uncertainty, Agile Teams conduct small experiments before moving to implementation, rather than speculate about the outcome or jump to a Solution. Teams may use spikes in a variety of situations: Estimate new Features and Capabilities to analyze the implied behavior, providing insight about the approach for splitting them into smaller, quantifiable pieces Perform feasibility analysis and other activities that help determine the viability of epics Conduct basic research to familiarize them with a new technology or domain Gain confidence in a technical or functional approach, reducing risk and uncertainty Spikes involve creating a small program, research activity, or test that demonstrates some aspect of new functionality. Technical and Functional Spikes Spikes primarily come in two forms: technical and functional. Functional spikes – They are used to analyze overall solution behavior and determine: How to break it down How to organize the work Where risk and complexity exist How to use insights to influence implementation decisions Technical spikes – They are used to research various approaches in the solution domain. For example: Determine a build-versus-buy decision Evaluate the potential performance or load impact of a new user story Evaluate specific technical implementation approaches Develop confidence about the desired solution path Some features and user stories may require both types of spikes. Here’s an example: “As a consumer, I want to see my daily energy use in a histogram so that I can quickly understand my past, current, and projected energy consumption.” In this case, a team might create both types of spikes: A technical spike to research how long it takes to update a customer display to current usage, determining communication requirements, bandwidth, and whether to push or pull the data A functional spike – Prototype a histogram in the web portal and get some user feedback on presentation size, style, and charting Guidelines for Spikes Since spikes do not directly deliver user value, use them sparingly. The following guidelines apply. Quantifiable, Demonstrable, and Acceptable Like other stories, spikes are put in the Team Backlog, estimated, and sized to fit in an iteration. Spike results are different from a story because spikes typically produce information rather than working code. They should develop only the necessary data to identify and size the stories that drive it confidently. The output of a spike is demonstrable, both to the team and to any other stakeholders, which brings visibility to the research and architectural efforts, and also helps build collective ownership and shared responsibility for decision-making. The Product Owner accepts spikes that have been demoed and meet its acceptance criteria. Timing of Spikes Since they represent uncertainty in one or more potential stories, planning for both the spike and the resulting stories in the same iteration is sometimes risky. However, if it’s small and straightforward, and a quick solution is likely to be found, then it can be quite efficient to do both in the same iteration. The Exception, Not the Rule Every user story has uncertainty and risk; that’s the nature of Agile development. The team discovers the right solution through discussion, collaboration, experimentation, and negotiation. Thus, in one sense, every user story contains spike-like activities to identify the technical and functional risks. The goal of an Agile team is to learn how to address uncertainty in each iteration. Spikes are critical when high uncertainty exist, or there are many unknowns.
Selecting between-sample RNA-Seq normalization methods from the perspective of their assumptions
Spliced synthetic genes as internal controls in RNA sequencing experiments
Fundamental Need for Spike-In Control for Virtually All Genome-Wide Analyses